Close menu




Comments

Photo credits: pixabay.com

Commented by André Will-Laudien on July 30th, 2025 | 07:00 CEST

Trump's Tariffs & Takeovers! BioNTech, PanGenomic Health, Pfizer, and Valneva Targeted by Speculators

  • Healthcare
  • healthtech
  • Biotechnology
  • Pharma

The US-EU tariff agreement has now been finalized. Many sectors of the European economy will now face additional burdens and margin cuts. The biotech and pharmaceutical industries have been spared, as medicines and active pharmaceutical ingredients are among the few product groups that are traditionally traded duty-free in transatlantic trade. This is due to international agreements, such as the WTO Pharmaceutical Agreement, which both the EU and the US have signed. Clinical trial drugs, active ingredient imports, and vaccines are also mostly exempt from tariffs. Valneva is currently making headlines with its chikungunya vaccine, BioNTech and Pfizer are continuing to sell COVID-19 vaccines on a small scale, and PanGenomic is surprising everyone with a new AI-powered health platform. A lot is going on in the sector – who are the big earners?

Read

Commented by Nico Popp on July 29th, 2025 | 07:30 CEST

Drone hype: Who is getting the best deal? Volatus Aerospace, Renault, Rheinmetall

  • Drones
  • aerospace
  • Defense
  • Technology

The days of tanks and howitzers are over. The war in Ukraine shows that drones are changing the face of combat—they provide reconnaissance, carry out precision strikes, and score points with low acquisition costs and high effectiveness. It is no wonder that major arms manufacturers and industrial companies want to jump on the drone bandwagon. Renault has even been asked by the French government to enter the business. But the barriers to entry in this market are high. We explain who is likely to profit from the drone business in the future and why size and capital are no guarantee of long-term success.

Read

Commented by Armin Schulz on July 29th, 2025 | 07:25 CEST

Hydrogen from setback to comeback: Plug Power, First Hydrogen, Nel ASA – Who will emerge victorious from the transformation?

  • Hydrogen
  • cleantech
  • greenhydrogen
  • renewableenergies

Quietly but steadily, the hydrogen revolution is regaining momentum! Despite short-term setbacks, pragmatic solutions are reigniting the fire. Core networks are emerging, logistics alliances are optimizing supply chains, and niche markets are beginning to thrive. Here, smart players are shaping decarbonization far removed from the overheated expectations of 2021. Three companies stand out: Plug Power, First Hydrogen, and Nel ASA. They combine strategic partnerships and specialized technologies, leveraging government infrastructure initiatives to emerge from the crisis as stronger winners.

Read

Commented by Nico Popp on July 29th, 2025 | 07:20 CEST

Study reveals AI catch-up gap among pharmaceutical giants: Opportunities for Roche, Pfizer, and NetraMark?

  • Biotechnology
  • Biotech
  • Pharma

Many observers believe that AI will revolutionize the biotech and pharmaceutical industries. A study by market researchers at Coherent Solutions now reveals the full picture: the market for biotechnology AI is projected to grow from USD 2.6 billion today to USD 12.8 billion by 2035. This corresponds to an annual growth rate of 18.8%. The report also shows how the industry's major players are preparing for the change. Since the "AI Readiness Index" calculated by the analysts paints a very complex picture, the opportunities for specialized AI investments are significant. We take a closer look at the Coherent Solutions study and introduce a business model poised to revolutionize pharmaceutical research and offer opportunities for investors.

Read

Commented by Fabian Lorenz on July 29th, 2025 | 07:15 CEST

Watch out for BioNTech! Bayer, Formycon, and Vidac Pharma shares are on the rise!

  • Biotechnology
  • Biotech
  • Pharma

While all eyes appear to be on BioNTech's upcoming quarterly results on August 4, other shares are on the rise. Analysts see strong upside potential for Vidac Pharma, citing the possibility of a multi-fold increase. The Company has appointed a new CEO, and its listing on a major German stock exchange is expected soon. This is an exciting mix that could break the sideways trend and ignite a rally. Bayer and Formycon have already shown that a 50% increase is possible in just a few months. However, the DAX-listed company had to report a delay in product approval last Friday. At Formycon, the upward trend is still intact. Analysts praise the progress made in biosimilar development.

Read

Commented by Armin Schulz on July 29th, 2025 | 07:10 CEST

RENK, Almonty Industries, thyssenkrupp: Three stocks that are benefiting NOW from the new security dividend

  • Mining
  • Tungsten
  • Defense

Geopolitical turmoil is accelerating growth in key sectors. As defense budgets rise worldwide and supply chains are realigned, specialized players are positioning themselves as indispensable partners. High demand for security-critical technology, strategic raw materials, and innovative industrial solutions is driving this development, giving selected companies extraordinary momentum. We take a look at RENK, Almonty Industries, and thyssenkrupp to see who is benefiting now.

Read

Commented by André Will-Laudien on July 29th, 2025 | 07:05 CEST

Trump tariffs settled? What are the triggers now? Palantir, naoo AG, TeamViewer, and D-Wave

  • Digitization
  • Technology
  • Software
  • computing

With the US-EU agreement on tariffs, markets opened positively yesterday but quickly slipped into negative territory. The reason: the agreement is widely viewed as a "loss-making deal" for the EU. While tariffs of over 20% were averted, 15% still remain. In return, NATO must purchase substantial US military equipment, while US vehicle exports to the EU remain tariff-free. Donald Trump could not have negotiated better himself - a diplomatic failure for Brussels. The decision will have a significant impact on the EU's automotive sector, luxury and consumer goods industries, and technology sector. For example, European wine will cost US consumers about 30% more, factoring in currency losses, which is devastating for European winemakers. All in all, this deal is considered a major setback for free trade, with serious inflationary consequences and declining consumer demand. Investors should reposition themselves, as late summer looks stormy from this perspective alone.

Read

Commented by Fabian Lorenz on July 29th, 2025 | 07:00 CEST

YIELD MONSTERS 2025: Hensoldt, Steyr Motors, Veganz shares – another 250% gain?

  • Vegan
  • Food
  • Defense
  • Automotive

When it comes to German return monsters for 2025, investors rightly think primarily of defense companies like Rheinmetall, RENK, Hensoldt, and Steyr Motors. However, with a 250% gain, the Veganz Group may well be the surprise of the year. The Company is currently reinventing itself and attacking a billion-dollar market. Analyst estimates appear to be far too conservative and are likely to be revised upward soon. The stock, therefore, remains very attractive. Hensoldt has multiplied in value in recent years and is now supplying radar systems for the protection of Ukraine. The order volume is in the mid-three-digit million range. Steyr Motors will have to grow to this revenue range in the coming years to justify its current valuation. Analysts nevertheless recommend buying the stock.

Read

Commented by André Will-Laudien on July 28th, 2025 | 07:25 CEST

Gold and silver rally in 2025 – Panic buying ahead! Silver North, BYD, and VW in the fast lane!

  • Mining
  • Silver
  • Gold
  • Commodities
  • Electromobility

Silver has long since ceased to be gold's little brother! Over the past 12 months, silver has clearly outperformed its big brother, rising 38% compared to a 27% increase in gold. This is due to several factors. Firstly, there are only around 240 active silver mines worldwide, compared to 1,350 gold mines. In recent years, silver has established itself as an industrial metal, as it is in high demand in high-tech, e-mobility, defense, and medical applications. This means that less and less of the coveted metal is left for the investment market, and physical stocks on the futures markets are also declining steadily. The time has therefore come to allocate some of your portfolio to silver, the little brother of gold, which has performed well. Silver explorers and developers offer the greatest leverage. Here are a few ideas.

Read

Commented by Nico Popp on July 28th, 2025 | 07:20 CEST

Hydrogen in Germany – Who will solve the "chicken and egg problem"? Pure Hydrogen, thyssenkrupp, NEL

  • Hydrogen
  • renewableenergies
  • cleantech

Germany aims to achieve climate neutrality within twenty years. Hydrogen plays a crucial role in making industry more sustainable. However, as a recent article in Focus magazine shows, Germany has a "chicken and egg problem" when it comes to hydrogen. Planning security is needed to drive the necessary investment in hydrogen infrastructure. But industry is still hesitant, especially in uncertain times; no one wants to stick their neck out too far. This, in turn, does not provide an environment conducive to launching essential prerequisites, such as pipelines, storage facilities, or decentralized electrolysers. What does the future hold for Germany as a hydrogen location? Which stocks could benefit?

Read